Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | PIK3R1 | P27986 | 5/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.37 |
| ▸ | MTOR | P42345 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL302488 | 0.88 | ALDH1A1 (0.39) | ALDH1A1NPSR1LMNAPOLBSMN1; SMN2 | |
| SCHEMBL302616 | 0.88 | MAPT (0.41) | ALDH1A1NPSR1LMNAPOLBSMN1; SMN2 | |
| SCHEMBL302260 | 0.85 | CYP3A4 (0.45) | ALDH1A1NPSR1POLBSMN1; SMN2MAPK1 | |
| SCHEMBL302262 | 0.85 | CYP3A4 (0.45) | ALDH1A1NPSR1POLBSMN1; SMN2MAPK1 | |
| SCHEMBL303501 | 0.85 | ATR (0.41) | ALDH1A1NPSR1LMNASMN1; SMN2PIK3CA | |
| SCHEMBL303591 | 0.85 | SMN1; SMN2 (0.38) | ALDH1A1NPSR1LMNAPOLBSMN1; SMN2 | |
| SCHEMBL302649 | 0.83 | ALDH1A1 (0.43) | ALDH1A1NPSR1LMNAPOLBSMN1; SMN2 | |
| SCHEMBL303890 | 0.81 | ALDH1A1 (0.42) | ALDH1A1NPSR1LMNAPOLBSMN1; SMN2 | |
| SCHEMBL302102 | 0.80 | ALDH1A1 (0.38) | ALDH1A1NPSR1LMNAPOLBSMN1; SMN2 | |
| SCHEMBL302828 | 0.79 | SMN1; SMN2 (0.38) | ALDH1A1NPSR1LMNAPOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-25 | — | — | US | disclosed |
| US-20120021434-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-04-28 | — | — | US | disclosed |
| US-20090163708-A1 | PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | IL17A, IL23R, IL15 | ALDH1A1 1903/4885NPSR1 1956/4885LMNA 3847/4885 |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | REL, NFATC1, BCL6 | ALDH1A1 3468/4885NPSR1 2514/4885LMNA 3579/4885 |
| US-20090163708-A1 | PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS | IL17A, IL23R, IL2 | ALDH1A1 747/4885NPSR1 2392/4885LMNA 3835/4885 |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | REL, NFATC1, BCL6 | ALDH1A1 3468/4885NPSR1 2514/4885LMNA 3579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.